Listing 3 - Actual negotiations

Indication:

Osteoporosis

Indication:

Non-small cell lung cancer (NSCLC), locally advanced unresectable metastatic, harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations, in adult patients

Indication:

Migraine, prevention

Indication:

Amyotrophic Lateral Sclerosis (ALS)

Indication:

Deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer, for adjuvant treatment of adult patients who have been treated with neoadjuvant or adjuvant chemotherapy

Indication:

Vasomotor symptoms associated with menopause

Indication:

Unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adult patients who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy

Indication:

Resectable Non-small cell lung cancer (tumours ?4cm or node positive), neoadjuvant treatment of adult patients, when used in combination with platinum-doublet chemotherapy

Indication:

Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients

Indication:

Multiple myeloma (MM) in adults with who have received at least one prior therapy (In combination with bortezomib (V) and dexamethasone (d))